Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,326,610
  • Shares Outstanding, K 59,081
  • Annual Sales, $ 43,100 K
  • Annual Income, $ -99,530 K
  • 60-Month Beta 1.59
  • Price/Sales 49.15
  • Price/Cash Flow N/A
  • Price/Book 6.43
Trade NTLA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.58
  • Number of Estimates 8
  • High Estimate -0.38
  • Low Estimate -0.76
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -1.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.49 +67.65%
on 10/30/20
39.44 -0.15%
on 11/27/20
+13.94 (+54.80%)
since 10/27/20
3-Month
16.54 +138.09%
on 09/04/20
39.44 -0.15%
on 11/27/20
+18.91 (+92.38%)
since 08/27/20
52-Week
9.18 +328.98%
on 03/16/20
39.44 -0.15%
on 11/27/20
+22.38 (+131.58%)
since 11/27/19

Most Recent Stories

More News
First Week of July 2021 Options Trading For Intellia Therapeutics (NTLA)

Investors in Intellia Therapeutics Inc saw new options become available this week, for the July 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

NTLA : 39.38 (+9.82%)
Market Takes a Well-Deserved Rest

Market Takes a Well-Deserved Rest

CCRN : 9.39 (+0.75%)
CENTA : 37.28 (+0.87%)
ENR : 41.83 (-0.43%)
MAXR : 28.54 (+0.18%)
PRPL : 30.67 (+5.03%)
NTLA : 39.38 (+9.82%)
MRNA : 127.03 (+16.35%)
HBI : 14.43 (-0.48%)
FIZZ : 94.90 (-0.17%)
CWH : 31.27 (+2.69%)
BIDU : 139.42 (+2.51%)
SYY : 71.24 (-0.61%)
MAR : 128.35 (-0.67%)
ALC : 63.79 (+0.97%)
SQM : 48.15 (-0.39%)
AYX : 119.45 (+1.76%)
CDAY : 99.39 (+3.46%)
GDS : 90.72 (+5.35%)
HXL : 51.90 (-0.10%)
LVS : 56.59 (+0.09%)
NFLX : 491.36 (+1.31%)
AMZN : 3,195.34 (+0.32%)
TSLA : 585.76 (+2.05%)
PFE : 37.23 (+1.92%)
3 Top Biotech Stocks for 2021

While many growth stocks are selling-off on the vaccine news, one growth sector that should keep outperforming in 2021 is biotech stocks. Some of the best ones to consider are Moderna (MRNA), Intellia...

MRNA : 127.03 (+16.35%)
NTLA : 39.38 (+9.82%)
MNKD : 3.08 (+4.41%)
3 Biotech Stocks Set to Soar in 2021

As Pfizer (PFE) announced that its COVID-19 vaccine candidate is 90% effective, biotech stocks are on fire. These stocks have seen a bull-run since the beginning of 2020 and are expected to witness the...

JAZZ : 143.28 (+1.02%)
ARWR : 62.99 (+10.47%)
UTHR : 135.54 (+0.35%)
NTLA : 39.38 (+9.82%)
3 Biotech Stocks With 10-BAGGER Potential

Biotechs offer investors exposure to growth. Within biotechs, genomics is one of the areas with the most potential due to the ability to treat diseases or heal the body at the cellular or DNA level. NTLA,...

NTLA : 39.38 (+9.82%)
CRSP : 121.55 (+10.50%)
EDIT : 31.34 (+6.42%)
IBB : 143.22 (+3.07%)
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

TMO : 453.40 (+1.10%)
VRTX : 226.71 (+3.95%)
EBS : 82.83 (+3.01%)
EDIT : 31.34 (+6.42%)
CLLS : 24.21 (+7.98%)
NTLA : 39.38 (+9.82%)
CRSP : 121.55 (+10.50%)
NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

AGYS : 38.43 (-0.08%)
NTLA : 39.38 (+9.82%)
EDIT : 31.34 (+6.42%)
CRSP : 121.55 (+10.50%)
SGMO : 10.12 (+3.58%)
HEAR : 19.11 (+3.86%)
JPM : 121.22 (-0.66%)
C : 56.67 (-0.68%)
BAC : 28.99 (-0.14%)
GS : 235.40 (-0.48%)
MS : 63.84 (+0.57%)
Stocks Jump More Than 1% on Revived Stimulus Hopes

Stocks Jump More Than 1% on Revived Stimulus Hopes

WSO : 223.09 (-0.29%)
EGAN : 11.78 (+3.06%)
ZS : 149.74 (+1.91%)
MODN : 33.82 (+1.38%)
G : 41.11 (+0.22%)
NTLA : 39.38 (+9.82%)
QDEL : 188.00 (+4.01%)
AAL : 14.98 (+0.27%)
UAL : 45.30 (-0.74%)
CCL : 21.58 (+4.50%)
RCL : 81.48 (+1.75%)
NFLX : 491.36 (+1.31%)
AMZN : 3,195.34 (+0.32%)
AAPL : 116.59 (+0.48%)
Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

Two women will share the Nobel prize for a gene editing technology that will change the world.

NVDA : 530.45 (+0.20%)
QDEL : 188.00 (+4.01%)
EDIT : 31.34 (+6.42%)
TTD : 873.10 (+1.26%)
NTLA : 39.38 (+9.82%)
CRSP : 121.55 (+10.50%)
AYX : 119.45 (+1.76%)
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

VRTX : 226.71 (+3.95%)
EDIT : 31.34 (+6.42%)
NTLA : 39.38 (+9.82%)
CRSP : 121.55 (+10.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

2nd Resistance Point 41.97
1st Resistance Point 40.68
Last Price 39.38
1st Support Level 36.85
2nd Support Level 34.31

See More

52-Week High 39.44
Last Price 39.38
Fibonacci 61.8% 27.88
Fibonacci 50% 24.31
Fibonacci 38.2% 20.74
52-Week Low 9.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar